Preference for buprenorphine/naloxone and buprenorphine among patients receiving buprenorphine maintenance therapy in France: A prospective, multicenter study

Journal of Substance Abuse Treatment

Volumn 38, Issue 1, 2010, Pages 83-89

  Daulouède, Jean Pierre ^a   Caer, Yves ^b   Galland, Pascal ^c   Villeger, Pierre ^d   Brunelle, Emmanuel ^e   Bachellier, Jérôme ^f   Piquet, Jean Michel ^g   Harbonnier, Jean ^h   Leglise, Yves ⁱ   Courty, Pascal ^j  

^a Ctr Toxicomanes Prog M M R   (France)

^b DEPARTMENT OF NEUROLOGY   (France)

^c Centre Hospitalier Beziers   (France)

^d CENTRE HOSPITALIER ESQUIROL   (France)

^e Centre Hospitalier de LENS   (France)

^f Centre Port Bretagne   (France)

^g CSST Le Cèdre bleu   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ MONTPELLIER UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

more..

Author keywords

Buprenorphine; Heroin; Misuse; Naloxone; Opioids

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSAGE FORM COMPARISON; DRUG INDUCED HEADACHE; DRUG PREFERENCE; DRUG RESPONSE; DRUG SOLUBILITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FLATULENCE; FRANCE; HUMAN; HYPERHIDROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPIATE ADDICTION; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; SOMNOLENCE; TABLET FORMULATION; VERTIGO;

ADOLESCENT; ADULT; BUPRENORPHINE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; FRANCE; HEROIN DEPENDENCE; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; PATIENT PREFERENCE; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 70849115778     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2009.07.002     Document Type: Article

References (18)

1. Alho H., Sinclair D., Vuori E., and Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug and Alcohol Dependence 88 (2007) 75-78
2. Auriacombe M., Franques-Reneric P., Daulouede J.P., and Tignol J. Buprenorphine prescribed by general practitioners-a safe means of increasing patient access to treatment?. In: Waal H., and Haga E. (Eds). Maintenance treatment of heroin addiction: Evidence at the crossroads (2003), Cappelen Academic Press, Oslo, Norway 190-204
3. Bachert C., and El Akkad T. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Annals of Allergy, Asthma & Immunology 89 (2002) 292-297
4. Barry D.T., Moore B.A., Pantalon M.V., Chawarski M.C., Sullivan L.E., O'Connor P.G., Schottenfeld R.S., and Fiellin D.A. Patient satisfaction with primary care office-based buprenorphine/naloxone treatment. Journal of General Internal Medicine 22 (2007) 242-245
5. Bell J., Shanahan M., Mutch C., Rea F., Ryan A., Batey R., Dunlop A., and Winstock A. A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction 102 (2007) 1899-1907
6. Carrieri M.P., Amass L., Lucas G.M., Vlahov D., Wodak A., and Woody G.E. Buprenorphine use: The international experience. Clinical Infectious Diseases 43 (2006) S197-S215
7. Emmanuelli J., and Desenclos J.C. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. Addiction 100 (2005) 1690-1700
8. Fatseas M., and Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Current Psychiatry Reports 9 (2007) 358-364
9. Fiellin D.A., Moore B.A., Sullivan L.E., Becker W.C., Pantalon M.V., Chawarski M.C., Barry D.T., O'Connor P.G.R., and Schottenfeld R.S. Long-term treatment with buprenorphine/naloxone in primary care: Results at 2-5 years. American Journal on Addictions 17 (2008) 116-120
10. Fiellin D.A., Pantalon M.V., Chawarski M.C., Moore B.A., Sullivan L.E., O'Connor P.G., and Schottenfeld R.S. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. New England Journal of Medicine 355 (2006) 365-374
11. Finch J.W., Kamien J.B., and Amass L. Two-year experience with buprenorphine-naloxone (Suboxone) for maintenance treatment of opioid dependence within a private practice setting. Journal of Addictive Medicine 1 (2007) 104-110
12. Gueye P.N., Megarbane B., Borron S.W., Adnet F., Galliot-Guilley M., Ricordel I., et al. Trends in opiate and opioid poisonings in addicts in north-east Paris and suburbs, 1995-99. Addiction 97 (2002) 1295-1304
13. International Harm Reduction Association. Busy month for IHRA: October 2006. Available at: (2006). http://www.ihra.net/October2006 Accessed on: April 8, 2008
14. Mendelson J., and Jones R.T. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: Why the 4:1 ratio for treatment?. Drug and Alcohol Dependence 70 (2003) S29-S37
15. Obadia Y., Perrin V., Feroni I., Vlahov D., and Moatti J.P. Injecting misuse of buprenorphine among French drug users. Addiction 96 (2001) 267-272
16. Simojoki K., Vorma H., and Alho H. A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone). Substance Abuse Treatment, Prevention, and Policy 3 (2008)
17. Stoller K.B., Bigelow G.E., Walsh S.L., and Strain E.C. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl) 154 (2001) 230-242
18. Vidal-Trecan G., Varescon I., Nabet N., and Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug and Alcohol Dependence 69 (2003) 175-181